Antisense Therapeutics says it initiated process for submission of atl1102 for multiple sclerosis...

April 24 (Reuters) - Antisense Therapeutics Ltd (ANP)

  • Initiated process for submission of atl1102 for multiple sclerosis (ms) phase iib ind application with documentation being provided to its regulatory agent in us


To read reuters' full disclaimer click here
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.